VERTEX PHARMACEUTICALS
Vertex Pharmaceuticals is a biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.
VERTEX PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
1989-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.vrtx.com
Total Employee:
1001+
Status:
Active
Contact:
617-341-6100
Email Addresses:
[email protected]
Total Funding:
656.2 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Font Awesome Domain Not Resolving Mobile Non Scaleable Content Nginx
Similar Organizations
CMTx Biotech
CMTx Biotech focuses on repurposing a clinical-stage small molecule for the treatment of COVID-19 patients.
Eli Lilly
Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
GlycoBioChem
GlycoBioChem is focused on discovery and development of novel small-molecules for the purposes of research and treatment of human diseases.
GT Biopharma
GT Biopharma specializes in the research and development of therapeutic products used primarily for the treatment of cancer.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Signal Pharma Ltd.
Signal Pharma Ltd. focus on the discovery and preclinical development of drugs for the treatment of diseases.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-07-11 | ViaCyte | ViaCyte acquired by Vertex Pharmaceuticals | 320 M USD |
| 2022-03-07 | Vectrus | Vectrus acquired by Vertex Pharmaceuticals | 2.1 B USD |
| 2019-09-03 | Semma Therapeutics | Semma Therapeutics acquired by Vertex Pharmaceuticals | 950 M USD |
| 2019-06-06 | Exonics Therapeutics | Exonics Therapeutics acquired by Vertex Pharmaceuticals | 245 M USD |
| 2001-04-30 | Aurora Biosciences Corporation | Aurora Biosciences Corporation acquired by Vertex Pharmaceuticals | N/A |
Investors List
J.P. Morgan Securities Inc.
J.P. Morgan Securities Inc. investment in Post-IPO Equity - Vertex Pharmaceuticals
Bank of America Merrill Lynch
Bank of America Merrill Lynch investment in Post-IPO Equity - Vertex Pharmaceuticals
Morgan Stanley
Morgan Stanley investment in Post-IPO Equity - Vertex Pharmaceuticals
Goldman Sachs
Goldman Sachs investment in Post-IPO Equity - Vertex Pharmaceuticals
Janssen Belgium
Janssen Belgium investment in Post-IPO Equity - Vertex Pharmaceuticals
Norwest Venture Partners
Norwest Venture Partners investment in Venture Round - Vertex Pharmaceuticals
J.H. Whitney & Co
J.H. Whitney & Co investment in Venture Round - Vertex Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Venture Round - Vertex Pharmaceuticals
Greylock
Greylock investment in Venture Round - Vertex Pharmaceuticals
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-11-09 | Arbor Biotechnologies | Vertex Pharmaceuticals investment in Series B - Arbor Biotechnologies | 215 M USD |
| 2020-03-12 | Kymera Therapeutics | Vertex Pharmaceuticals investment in Series C - Kymera Therapeutics | 102 M USD |
| 2018-12-09 | Genomics | Vertex Pharmaceuticals investment in Series B - Genomics | 8 M EUR |
| 2018-08-30 | Genomics | Vertex Pharmaceuticals investment in Series B - Genomics | 25 M GBP |
| 2015-04-30 | CRISPR Therapeutics | Vertex Pharmaceuticals investment in Series B - CRISPR Therapeutics | 29 M USD |
Newest Events participated
Participated in Forbes Under 30 Summit 2016
on 2016-10-16 as sponsor
Key Employee Changes
| Date | New article |
|---|---|
| 2021-08-04 | Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer |
Official Site Inspections
http://www.vrtx.com Semrush global rank: 394.34 K Semrush visits lastest month: 141.96 K
- Host name: 45.60.0.246
- IP address: 45.60.0.246
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
